Posted by Kevin Yang ⎜ Jun 6, 2018 ⎜ Industry
A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2
Info on purchasing Ac-225, please contact firstname.lastname@example.org .